AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28360027 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections
Number of subjects: 317
Study 25467848 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT2 250 mg
Number of subjects: 109
Study 25467848 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT2 100 mg
Number of subjects: 109
Study 25467848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 24642073 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute nicotine ingestion
Number of subjects: 22
Study 24642073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22808020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rinse (60 seconds with chlorhexidine followed by 60 seconds with nystatin)
Number of subjects: 220
Study 22808020 — intervention group
Group type: COMPARATOR
Intervention: No oral rinse
Number of subjects: 220
Study 21135327 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 268
Study 21135327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 17952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (L)
Number of subjects: 88
Study 17952581 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (D)
Number of subjects: 88
Study 17952581 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 88
Study 15590210 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT every day (0.625 mg CEE and 2.5 mg MPA)
Number of subjects: 137
Study 15590210 — intervention group
Group type: COMPARATOR
Intervention: HRT every other day (0.625 mg CEE and 2.5 mg MPA)
Number of subjects: 137
Study 12199798 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) for 5-7 days
Number of subjects: 1137
Study 12199798 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) reviparin for 5-7 days (short-treated group)
Number of subjects: 1137
Study 12199798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) reviparin for 28 days (long-treated group)
Number of subjects: 1137
Study 9498541 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative clinical seizures
Number of subjects: 171
Study 9498541 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative EEG seizures
Number of subjects: 171
Study 9498541 — intervention group
Group type: COMPARATOR
Intervention: No seizures (control group)
Number of subjects: 171
Study 8919444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy device fitted in the operating room
Number of subjects: 50
Study 8919444 — intervention group
Group type: COMPARATOR
Intervention: Noncryotherapy group
Number of subjects: 50
Study 1811606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma immunoglobulin (IVIG)
Number of subjects: 372
Study 1811606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 6138116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 63
Study 6138116 — intervention group
Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 63
Study 30757935 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipta prostrata (EP) 1 mg/day
Number of subjects: 16
Study 30757935 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipta prostrata (EP) 10 mg/day
Number of subjects: 16
Study 30757935 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 3% minoxidil
Number of subjects: 16
Study 30757935 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 16
Study 30289329 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) treatment (4 times daily in both eyes for a month before HSCT and continued use after transplantation)
Number of subjects: 58
Study 30289329 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 58
Study 25923229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (rabeprazole 20 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by rabeprazole 20 mg twice daily, tinidazole 500 mg twice daily plus clarithromycin 500 mg twice daily for another 5 days)
Number of subjects: 199
Study 25923229 — intervention group
Group type: COMPARATOR
Intervention: Modified bismuth-included quadruple therapy (rabeprazole 20 mg twice daily, levofloxacin hydrochloride 400 mg twice daily, clarithromycin 500 mg twice daily, and colloidal bismuth pectin 200 mg 3 times a day for 7 days)
Number of subjects: 199
Study 25923229 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (sequential therapy and modified bismuth-included quadruple therapy)
Number of subjects: 199
Study 24435939 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-Factor Stress Test (FFST)
Number of subjects: 90
Study 24435939 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 90
Study 24435939 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo version of FFST)
Number of subjects: 90
Study 23203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led recovery group (Vet-to-Vet)
Number of subjects: 240
Study 23203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led recovery group
Number of subjects: 240
Study 23203360 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 240
Study 23203360 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 240
Study 23203360 — intervention group
Group type: EXPERIMENTAL
Intervention: Group attendance
Number of subjects: 240
Study 19529955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography combined with BIJV‐IOPTH
Number of subjects: 78
Study 19529955 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography alone
Number of subjects: 78
Study 19529955 — intervention group
Group type: EXPERIMENTAL
Intervention: BIJV‐IOPTH
Number of subjects: 78
Study 19529955 — intervention group
Group type: COMPARATOR
Intervention: Open neck explorations (unilateral)
Number of subjects: 78
Study 19529955 — intervention group
Group type: COMPARATOR
Intervention: Open neck explorations (bilateral)
Number of subjects: 78
Study 17310303 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg, administered twice within 12 h)
Number of subjects: 182
Study 17310303 — intervention group
Group type: COMPARATOR
Intervention: Propacetamol (2 g, administered twice within 12 h)
Number of subjects: 182
Study 17310303 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 182
Study 17310303 — intervention group
Group type: COMPARATOR
Intervention: Propacetamol
Number of subjects: 182
Study 15362796 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (group III)
Number of subjects: 102
Study 15362796 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (group II)
Number of subjects: 102
Study 15362796 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (group I)
Number of subjects: 102
Study 11219482 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg
Number of subjects: 71
Study 11219482 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg
Number of subjects: 71
Study 9886530 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 3 transfer of cleavage stage embryos (3.7 embryos transferred)
Number of subjects: 100
Study 9886530 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5 transfer of blastocysts (2.2 embryos transferred)
Number of subjects: 100
Study 9886530 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of 2 blastocysts
Number of subjects: 100
Study 9886530 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer of 3 blastocysts
Number of subjects: 100
Study 9886530 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst culture and transfer
Number of subjects: 100
Study 9886530 — intervention group
Group type: EXPERIMENTAL
Intervention: Thaw and transfer of cryopreserved blastocysts
Number of subjects: 100
Study 9013242 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA respirator
Number of subjects: 0
Study 9013242 — intervention group
Group type: COMPARATOR
Intervention: N-95 masks
Number of subjects: 0
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg once a day (o.d.)
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg once a day (o.d.)
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg twice a day (b.i.d.)
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg twice a day (b.i.d.)
Number of subjects: 25
Study 2697728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg o.d.
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg o.d.
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg b.i.d.
Number of subjects: 25
Study 2697728 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg b.i.d.
Number of subjects: 25
Study 11424 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsalmide
Number of subjects: 20
Study 11424 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 20
Study 30874716 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation (n=1108)
Number of subjects: 2204
Study 30874716 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (n=1096)
Number of subjects: 2204
Study 29953782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal combined with intravenous neoadjuvant chemotherapy
Number of subjects: 108
Study 29953782 — intervention group
Group type: COMPARATOR
Intervention: Cytoreductive surgery and six to eight courses of intravenous chemotherapy
Number of subjects: 108
Study 26346592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg
Number of subjects: 2155
Study 26346592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 2155
Study 26346592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg
Number of subjects: 2155
Study 26346592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 2155
Study 26346592 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 5 mg (elderly patients)
Number of subjects: 2155
Study 26346592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2155
Study 23187038 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked one-third tubular bridge plating
Number of subjects: 8
Study 23187038 — intervention group
Group type: COMPARATOR
Intervention: Standard one-third tubular bridge plating
Number of subjects: 8
Study 21530937 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1540
Study 21530937 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1540
Study 21530937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 1540
Study 19082404 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 x 0.70 mm needle
Number of subjects: 54
Study 19082404 — intervention group
Group type: COMPARATOR
Intervention: 20 x 0.55 mm needle
Number of subjects: 54
Study 16856900 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement (UD)
Number of subjects: 37
Study 16856900 — intervention group
Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing (Q-SRP)
Number of subjects: 37
Study 12767084 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations about screening
Number of subjects: 0
Study 12767084 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations plus tailored discussion (on beliefs, feelings, costs, and access)
Number of subjects: 0
Study 12767084 — intervention group
Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 0
Study 11127214 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate for 56 weeks
Number of subjects: 98
Study 11127214 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 56 weeks
Number of subjects: 98
Study 9303505 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b for 6 months
Number of subjects: 211
Study 9303505 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b for 12 months
Number of subjects: 211
Study 8285939 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann keratometry performed by a single masked observer
Number of subjects: 71
Study 8285939 — intervention group
Group type: COMPARATOR
Intervention: Javal‐Schiotz Keratometry performed by an independent observer
Number of subjects: 71
Study 8285939 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann keratometry
Number of subjects: 71
Study 2943781 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency angioplasty
Number of subjects: 28
Study 2943781 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary streptokinase
Number of subjects: 28
Study 30157357 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine combined with coenzyme Q10
Number of subjects: 262
Study 30157357 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B1 (placebo control)
Number of subjects: 262
Study 26864193 — intervention group
Group type: EXPERIMENTAL
Intervention: IP ketorolac 30 mg + intravenous saline
Number of subjects: 120
Study 26864193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 120
Study 26864193 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal saline + intravenous saline
Number of subjects: 120
Study 24827696 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB) - femoral nerve block and sciatic nerve block
Number of subjects: 210
Study 24827696 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection analgesia (PAI) - mixture of ropivacaine, saline, epinephrine, morphine hydrochloride, and dexamethasone
Number of subjects: 210
Study 24827696 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PNB and PAI)
Number of subjects: 210
Study 22495621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 (5 or 10mg/day)
Number of subjects: 639
Study 22495621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study 22495621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 (double-blind)
Number of subjects: 639
Study 22495621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind)
Number of subjects: 639
Study 22495621 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AA21004 (open-label)
Number of subjects: 639
Study 20828380 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical approach with separate suturing of internal and external anal sphincter muscles using monofilament absorbable sutures
Number of subjects: 26
Study 20828380 — intervention group
Group type: COMPARATOR
Intervention: Historical control group of women with prior OASI (n = 180)
Number of subjects: 26
Study 20828380 — intervention group
Group type: COMPARATOR
Intervention: Historical control group of primiparous women delivered vaginally without a diagnosis of OASI (n = 100)
Number of subjects: 26
Study 17698323 — intervention group
Group type: EXPERIMENTAL
Intervention: First Rank Symptoms (FRSs) present at baseline
Number of subjects: 388
Study 17698323 — intervention group
Group type: COMPARATOR
Intervention: No First Rank Symptoms (FRSs) at baseline
Number of subjects: 388
Study 16135141 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB311 nm therapy
Number of subjects: 9
Study 16135141 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol with UVB311 nm
Number of subjects: 9
Study 16135141 — intervention group
Group type: COMPARATOR
Intervention: Broad-band UVB therapy
Number of subjects: 9
Study 16135141 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (DLQI score)
Number of subjects: 9
Study 12192323 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized amino acid mixture (14 g arginine, 3 g HMB, 14 g glutamine)
Number of subjects: 35
Study 12192323 — intervention group
Group type: COMPARATOR
Intervention: Control group (isonitrogenous, isocaloric supplementation of nonessential amino acids)
Number of subjects: 35
Study 10201863 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified isotonic SELG preparation with 7.5 g/l of magnesium sulphate (SELG-Mg)
Number of subjects: 120
Study 10201863 — intervention group
Group type: COMPARATOR
Intervention: Standard isotonic PEG‐ELS (SELG)
Number of subjects: 120
Study 10201863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SELG and SELG-Mg)
Number of subjects: 120
Study 7828294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (20 mg/d)
Number of subjects: 15
Study 7828294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg/d)
Number of subjects: 15
Study 7828294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg/d)
Number of subjects: 15
Study 7828294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/d)
Number of subjects: 15
Study 7828294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2388639 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (3.2 g for 12 weeks, increased to 4.8 g for an additional 12 weeks)
Number of subjects: 20
Study 2388639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical amount for 12 weeks)
Number of subjects: 20
Study 30106956 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of mass azithromycin distribution (annual or twice yearly)
Number of subjects: 3938
Study 30106956 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of mass azithromycin distribution
Number of subjects: 3938
Study 30106956 — intervention group
Group type: COMPARATOR
Intervention: Comparison of continuation vs discontinuation
Number of subjects: 3938
Study 27769775 — intervention group
Group type: EXPERIMENTAL
Intervention: With-stylet technique
Number of subjects: 121
Study 27769775 — intervention group
Group type: COMPARATOR
Intervention: Without-stylet technique
Number of subjects: 121
Study 25766941 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 296
Study 25766941 — intervention group
Group type: COMPARATOR
Intervention: IRA-only revascularization
Number of subjects: 296
Study 22986466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 18
Study 22986466 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 18
Study 22986466 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 21637969 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (8-16 mg/day)
Number of subjects: 0
Study 21637969 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5-5 mg/day)
Number of subjects: 0
Study 19675101 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (62% ALA, 5.4 g/d)
Number of subjects: 36
Study 19675101 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 36
Study 16967643 — intervention group
Group type: EXPERIMENTAL
Intervention: Faustlos program
Number of subjects: 124
Study 16967643 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 15382590 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy (French method of R. Meigne)
Number of subjects: 80
Study 15382590 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy
Number of subjects: 80
Study 11113956 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric bootstrap methods for comparing arithmetic mean costs
Number of subjects: 0
Study 11113956 — intervention group
Group type: COMPARATOR
Intervention: Standard parametric methods
Number of subjects: 0
Study 11113956 — intervention group
Group type: COMPARATOR
Intervention: Randomization test
Number of subjects: 0
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 902
Study 9039073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 902
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 902
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 902
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 902
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 902
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 902
Study 9039073 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 902
Study 8100628 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume whole bowel irrigation (WBI)
Number of subjects: 6
Study 8100628 — intervention group
Group type: COMPARATOR
Intervention: Syrup of ipecac 30 ml followed by activated charcoal 50 g in sorbitol
Number of subjects: 6
Study 3826687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and oxygen
Number of subjects: 40
Study 3826687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane, oxygen, and nitrous oxide (63.5% end-tidal nitrous oxide)
Number of subjects: 40
Study 30892108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 15% Ointment applied twice a day for 2 months
Number of subjects: 30
Study 30892108 — intervention group
Group type: COMPARATOR
Intervention: Placebo Ointment applied twice a day for 2 months
Number of subjects: 30
Study 30322012 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA dietary counselling
Number of subjects: 119
Study 27664296 — intervention group
Group type: COMPARATOR
Intervention: 2mA anodal stimulation
Number of subjects: 150
Study 27664296 — intervention group
Group type: COMPARATOR
Intervention: 2mA cathodal stimulation
Number of subjects: 150
Study 27664296 — intervention group
Group type: COMPARATOR
Intervention: 1mA anodal stimulation
Number of subjects: 150
Study 27664296 — intervention group
Group type: COMPARATOR
Intervention: 1mA cathodal stimulation
Number of subjects: 150
Study 27664296 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 150
Study 24103486 — intervention group
Group type: EXPERIMENTAL
Intervention: RASS+BIS (BIS-augmented sedation)
Number of subjects: 300